SBIR Phase II: Transcranial Dynamic Focused Ultrasound for the Non-Invasive Opening of the Blood-Brain Barrier (BBB)

SBIR 第二阶段：经颅动态聚焦超声非侵入性打开血脑屏障 (BBB)

• 批准号: 2111810
• 负责人: Bhaskar Ramamurthy
• 金额: $ 99.85万
• 依托单位: CORDANCE MEDICAL INC.
• 依托单位国家: 美国
• 项目类别: Cooperative Agreement
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-07-15 至 2023-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2111810&HistoricalAwards=false
• 关键词: SBIR; Phase; II; Transcranial; Dynamic

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is to enable new therapeutic strategies to treat brain diseases such a brain cancer. Treating brain diseases is challenging partly because of the existence of an anatomical structure called the blood-brain barrier. This barrier prevents the entry of almost all therapeutic molecules into the brain tissue from the blood. This has led to a devastating impact on the patients and society as a whole. As an example, for glioblastoma, the most common form of primary malignant brain tumors, the five-year survival rate is only 6.8%. Impact and commercial potential include increased treatment options where few or none are available and improved patient outcomes, all with a system that is patient-friendly and designed to cause minimal disruption to the existing treatment workflows. Additionally, the advancement of this project will provide a convenient tool for drug developers to study and develop new drugs without the need to develop a special carrier to transport drugs into the brain. This Small Business Innovation Research (SBIR) Phase II project involves designing and building a prototype version of a system that can deliver therapies to the brain in a non-invasive and non-intrusive manner. The performance of this system to accurately deliver to regions of interest within the brain will be measured and characterized in a test environment mimicking that of a human head. This project will advance a prototype for use in both clinical and research settings.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这个小企业创新研究(SBIR)第二阶段项目的更广泛的影响/商业潜力是使新的治疗策略能够治疗脑部疾病，如脑癌。治疗脑部疾病具有挑战性，部分原因是存在一种名为血脑屏障的解剖结构。这种屏障阻止了几乎所有的治疗分子从血液进入脑组织。这对患者和整个社会都造成了毁灭性的影响。例如，胶质母细胞瘤是最常见的原发恶性脑肿瘤形式，其五年存活率仅为6.8%。影响和商业潜力包括在几乎没有可用的情况下增加治疗选择，以及改善患者结果，所有这些都带有一个对患者友好的系统，其设计对现有治疗工作流程的干扰最小。此外，该项目的推进将为药物开发者研究和开发新药提供便利的工具，而不需要开发专门的载体将药物输送到大脑中。这个小型企业创新研究(SBIR)第二阶段项目涉及设计和构建一个能够以非侵入性和非侵入性方式向大脑提供疗法的系统的原型版本。该系统准确传送到大脑内感兴趣区域的性能将在模拟人头的测试环境中进行测量和表征。该项目将推进用于临床和研究环境的原型。该奖项反映了NSF的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。